466 related articles for article (PubMed ID: 31159279)
1. GLP-1 Receptor Agonists and Kidney Protection.
Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
[TBL] [Abstract][Full Text] [Related]
2. Impact of CVOTs in primary and secondary prevention of kidney disease.
De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
[TBL] [Abstract][Full Text] [Related]
3. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
4. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
Thomas MC
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
[TBL] [Abstract][Full Text] [Related]
5. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.
Kuang Z; Hou N; Kan C; Han F; Qiu H; Sun X
Int Urol Nephrol; 2023 Mar; 55(3):617-629. PubMed ID: 36036316
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.
Górriz JL; Soler MJ; Navarro-González JF; García-Carro C; Puchades MJ; D'Marco L; Martínez Castelao A; Fernández-Fernández B; Ortiz A; Górriz-Zambrano C; Navarro-Pérez J; Gorgojo-Martinez JJ
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235471
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
[TBL] [Abstract][Full Text] [Related]
9. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.
Dieter BP; Alicic RZ; Tuttle KR
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1519-F1525. PubMed ID: 30110568
[TBL] [Abstract][Full Text] [Related]
11. Renal protection with glucagon-like peptide-1 receptor agonists.
Vitale M; Haxhi J; Cirrito T; Pugliese G
Curr Opin Pharmacol; 2020 Oct; 54():91-101. PubMed ID: 33027748
[TBL] [Abstract][Full Text] [Related]
12. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar MJB; van Raalte DH
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
[TBL] [Abstract][Full Text] [Related]
13. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
14. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
16. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
18. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
